1.
Rev Esp Enferm Dig
; 116(1): 43, 2024 Jan.
Article
in English
| MEDLINE
| ID: mdl-37073695
ABSTRACT
New immunosuppressive and antineoplastic drugs are becoming both more numerous and more widely used, even during several years. Most of them present a low-moderate risk of hepatitis B virus (HBV) reactivation in HBsAg-negative and anti-HBc-positive patients. However, their reactivation capacity has not been clearly studied. We present the clinical case of a patient with these serological characteristics who, after 5 years of treatment with ibrutinib for chronic lymphocytic leukaemia, developed VHB reactivation, which was controlled with tenofovir. The occurrence of this event with drugs such as ibrutinib may lead to changes in HBV reactivation prophylaxis.
Subject(s)
Adenine/analogs & derivatives , Hepatitis B virus , Hepatitis B , Humans , Hepatitis B/chemically induced , Hepatitis B Surface Antigens , Piperidines/pharmacology , Piperidines/therapeutic use , Virus Activation , Antiviral Agents/adverse effects
2.
Reactivación del virus de la hepatitis B por ibrutinib / Hepatitis B virus reactivation by ibrutinib
Rev. esp. enferm. dig
; 116(1): 43-43, 2024.
Article
in Spanish
| IBECS
| ID: ibc-229484
3.
Br J Haematol
; 177(5): 816-818, 2017 06.
Article
in English
| MEDLINE
| ID: mdl-27125335
Subject(s)
Immunoglobulin Light Chains , Lymphoma, Mantle-Cell , Humans , Ki-67 Antigen , Prognosis , Rituximab
4.
Med Clin (Barc)
; 131(19): 757-8, 2008 Nov 29.
Article
in Spanish
| MEDLINE
| ID: mdl-19091207
5.
Med. clín (Ed. impr.)
; 131(19): 757-758, nov. 2008.
Article
in Es
| IBECS
| ID: ibc-69592
ABSTRACT
No disponible
